Previous 10 | Next 10 |
Gainers: Kaleido Biosciences (KLDO) +15%, Pieris Pharmaceuticals (PIRS) +14%, Arcus Biosciences (RCUS) +14%, Compugen (CGEN) +14%, Atossa Therapeutics (ATOS) +14%.Losers: Portage Biotech (PRTG) -23%, Rite Aid (RAD) -14%, 4D Mole...
PPAMPicture/E+ via Getty Images Earnings news is moving shares of some household names on Thursday morning in pre-market trading. Drug store chain Rite Aid (RAD) dropped following the release of its quarterly report, while strong earnings sparked gains in shares of consulting firm Accenture (...
Marin Software Incorporated (MRIN) +63% on new InstaCart Ad Integration.India Globalization Capital (IGC) +22% on Alzheimer’s drug trial update.GTT Communications (GTT) +21%.Aravive, Inc. (ARAV) +20% on early-stage kidney cancer study data.Arcus Biosciences (RCUS) +19%...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Welcome to another busy day of trading, investor! We’re starting the day off with a look at the biggest pre-market stock movers for Thursday. Source: f11photo/Shutterstock.com Let’s jump into those pre...
- ARC-7 and the ongoing ARC-10 Phase 3 registrational study will continue to enroll as planned, and preparations for additional Phase 3 studies are underway for domvanalimab-based combinations across various cancer types - Zimberelimab monotherapy showed activity similar to th...
ASCO is a very important cancer clinical research meeting. We identified 70 smid-cap cancer companies presenting updated clinical data at ASCO21. 13 companies' value increased by over 10% with ASCO21 info release thus far. PDSB is an early ASCO21 mover, with its HPV vaccine ca...
In this first reported Phase 1b cohort, the etrumadenant-based combination was well tolerated with a composite overall response rate (ORR) of 41% in people previously treated for metastatic castrate-resistant prostate cancer (mCRPC) Etrumadenant is the first dual adenosine A...
Arcus Biosciences (RCUS): Q1 GAAP EPS of -$1.08 misses by $0.24.Revenue of $9.46M (+440.6% Y/Y) misses by $2.74M.Press Release For further details see: Arcus Biosciences EPS misses by $0.24, misses on revenue
Continued to advance our portfolio of anti-TIGIT antibodies: On track for the ARC-7 interim analysis for domvanalimab in 2Q21, and the first patient was dosed with AB308 in combination with zimberelimab Presented promising PFS and OS data for etrumadenant in the ≥...
Phase 1/1b results for the etrumadenant combination demonstrated a 4.2 month PFS, approximately double the 2 months reported for current standard of care therapies in the ≥3L mCRC setting ARC-9, a randomized Phase 1b/2 platform study, has been initiated to further evaluate ...
News, Short Squeeze, Breakout and More Instantly...
Arcus Biosciences Inc. Company Name:
RCUS Stock Symbol:
NYSE Market:
Arcus Biosciences Inc. Website:
Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, announced that its management team will host a conference call and webcast on Thursday, August 8 th , 2024 at 2 PM...
Arcus Biosciences, Inc. (NYSE:RCUS) and Taiho Pharmaceutical Co., Ltd. (“Taiho”) today announced that Taiho exercised its option for quemliclustat (International Nonproprietary Name; development code: AB680), an investigational small molecule CD73 inhibitor, in Japan and certain oth...
Domvanalimab is the only anti-TIGIT antibody in Phase 3 for upper gastrointestinal (GI) adenocarcinomas with the potential to be first-to-market for this patient population Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing di...